表紙
市場調查報告書

慢性骨髓性白血病(CML):開發中產品分析

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 192527
出版日期 內容資訊 英文 615 Pages
訂單完成後即時交付
價格
Back to Top
慢性骨髓性白血病(CML):開發中產品分析 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2019
出版日期: 2019年12月16日內容資訊: 英文 615 Pages
簡介

所謂慢性骨髓性白血病(CML)是指骨髓內部的造血細胞病變,並侵入血液的一種癌症。主要的風險因子有暴露在大量放射線下及年齡、性別等。主要症狀有疲勞感和倦怠感、盜汗、體重減輕,發熱,骨頭痛,脾臟肥大化,下腹部的疼痛和膨脹感等。主要的治療方法有放射線治療和造血細胞移植,化療等。

本報告提供全球各國治療慢性骨髓性白血病(CML)所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

慢性骨髓性白血病(CML)概要

治療藥的評估

開發治療藥的企業

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11699IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2019, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline landscape.

Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. Risk factors for CML include high-dose radiation, age and gender. Symptoms include weakness, fatigue, night sweats, weight loss, fever, bone pain, an enlarged spleen and pain or a sense of fullness in the belly. Treatment includes radiation therapy, blood cell transplantation and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 3, 29, 19, 2, 18, 6 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 9, 4, 6 and 3 molecules, respectively.

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Overview
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • Agios Pharmaceuticals Inc
  • Altor Bioscience LLC
  • Arromax Pharmatech Co Ltd
  • Ascentage Pharma Group International
  • AstraZeneca Plc
  • Atara Biotherapeutics Inc
  • AUM Biosciences Pte Ltd
  • Bio-Path Holdings Inc
  • BioLineRx Ltd
  • Boston Biomedical Inc
  • Bristol-Myers Squibb Co
  • Cantargia AB
  • Celgene Corp
  • Celularity Inc
  • Daiichi Sankyo Co Ltd
  • Escend Pharmaceuticals Inc
  • Eureka Therapeutics Inc
  • ExCellThera Inc
  • Fate Therapeutics Inc
  • Fusion Pharma LLC
  • Gamida Cell Ltd
  • GlaxoSmithKline Plc
  • GlycoMimetics Inc
  • GT Biopharma Inc
  • Handa Pharmaceuticals LLC
  • Hebei Senlang Biotechnology Inc Ltd
  • HEC Pharm Co Ltd
  • Helocyte Biosciences Inc
  • HighPass Bio Inc
  • Housey Pharmaceutical Research Laboratories LLC
  • Hovione FarmaCiencia SA
  • Ilyang Pharmaceutical Co Ltd
  • ImmunoForge Co Ltd
  • ImmunoGen Inc
  • Incysus Therapeutics Inc
  • Incyte Corp
  • Inhibikase Therapeutics Inc
  • Johnson & Johnson
  • Juno Therapeutics Inc
  • LG Chem Ltd
  • MAA Laboratories Inc
  • Magenta Therapeutics Inc
  • Mana Therapeutics Inc
  • MedPacto Inc
  • Millennium Pharmaceuticals Inc
  • Nanjing Sanhome Pharmaceutical Co Ltd
  • Natco Pharma Ltd
  • Nemucore Medical Innovations Inc
  • Neovia Oncology Inc
  • Nohla Therapeutics Inc
  • Novartis AG
  • OncoTherapy Science Inc
  • Ono Pharmaceutical Co Ltd
  • Pfizer Inc
  • Pharma Mar SA
  • PharmaEssentia Corp
  • Phylogica Ltd
  • Prescient Therapeutics Ltd
  • PRISM Pharma Co Ltd
  • Shenogen Pharma Group Ltd
  • Shouyao Holding Co Ltd
  • SignalChem Lifesciences Corp
  • Stemline Therapeutics Inc
  • Sun Pharma Advanced Research Company Ltd
  • Synactix Pharmaceuticals Inc
  • Takeda Pharmaceutical Co Ltd
  • Terns Pharmaceuticals Inc
  • TheraPharm Deutschland GmbH
  • Xencor Inc
  • Xspray Pharma AB
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Drug Profiles
  • (camptothecin + podofilox) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AIC-47 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ALT-803 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AMX-5035 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Antisense Oligonucleotide to Inhibit MIR126 for Chronic Myelocytic Leukemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • APG-1351 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • asciminib hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ATA-520 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AUM-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • azacitidine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • binimetinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BL-8040 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • bosutinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cellular Immunotherapy for Chronic Myeloid Leukemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cellular Immunotherapy for Hematological Malignancies - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cellular Immunotherapy for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cellular Immunotherapy for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ceralasertib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CT-413 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CYNK-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dasatinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dasatinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dilanubicel - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ECT-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ES-3000 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ET-019002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy for Chronic Myeloid Leukemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy for Leukemias - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Target CD19 and CD22 for Acute Lymphocytic Leukemia and Diffuse Large B-Cell Lymphoma - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Target CD19 for Blood Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Target CD20 for Blood Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Target CD22 for Blood Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Target GM-CSF for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GSK-3326595 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HD-30 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HND-030 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HND-033 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Hu8F4 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ICS-100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • imatinib mesylate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IMGN-632 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • inotuzumab ozogamicin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ipilimumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ivosidenib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ixazomib citrate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JTCR-016 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KF-1601 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lurbinectedin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MANA-677679 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MGTA-456 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • milademetan - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MJ-05 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody to Target CD66b for Blood Cancer and Metabolic Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • napabucasin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • nidanilimab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • nilotinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • nivolumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NMI-900 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NRCAN-019 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • omidubicel - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OTS-167 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OXS-3550 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pevonedistat hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PF-114 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ponatinib hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • prexigebersen - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PRI-724 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ProTmune - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • radotinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ropeginterferon alfa-2b - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ruxolitinib phosphate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • S-0071235 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SCO-088 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SENL-005 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SHC-004221A1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SL-501 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SLC-391 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule for Chronic Myelocytic Leukemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit ABL1 for Chronic Myeloid Leukemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit ADAR1 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit BCR-ABL for ALL and CML - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Bcr-Abl for CML and Pancreatic Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit SIRT1 for Chronic Myelogenous Leukemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SNG-1153 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SNG-162 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SUNK-0954 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SY-2755 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SYN-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptide to Inhibit STAT5 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TAK-243 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tipifarnib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TM-5614 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TR-120 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • triciribine phosphate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Triplex - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • uproleselan sodium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target Wilms Tumor Protein for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target WT1 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • vactosertib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • veliparib ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • venetoclax - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • XmAb-14045 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 10, 2019: Ascentage Pharma releases updated data of its novel BCR-ABL inhibitor, HQP1351, in an oral presentation nominated for "Best of ASH"
  • Nov 25, 2019: Data from Incyte's Oncology Portfolio including ponatinib hydrochloride accepted for presentation at the 61st Annual ASH Meeting
  • Nov 14, 2019: Ascentage Pharma to release updated data of its novel, third-generation BCR-ABL inhibitor, HQP1351, in Chinese chronic myeloid leukemia patients in an oral presentation at the 61st American Society of Hematology Annual Meeting
  • Nov 06, 2019: Takeda to present abstract on ICLUSIG at 61st American Society of Hematology (ASH) Annual Meeting
  • Jul 21, 2019: Ascentage Pharma to initiate phase Ib stuy of HQP1351 in tyrosine kinase inhibitors -resistant Chronic Myeloid Leukemia Patients in the US
  • Jul 08, 2019: SPARC receives Orphan Drug Designation from the USFDA for SCO-088 for the treatment of patients with chronic myeloid leukemia
  • Jun 14, 2019: Novartis presents on Asciminib at the 24th Congress of the European Hematology Association (EHA) in Amsterdam
  • Jun 11, 2019: Xspray granted additional product patents in the United States including HyNap-Nilo
  • May 16, 2019: Bristol-Myers Squibb to present new data on Sprycel at EHA 2019
  • Feb 19, 2019: Incyte provides statement on World Health Organization Global Medical Product alert for Iclusig (ponatinib)
  • Jan 18, 2019: EMA recommends extension of existing paediatric indications for Dasatinib
  • Jan 03, 2019: An errant editing enzyme promotes tumor suppressor loss and leukemia propagation
  • Dec 27, 2018: Bio-Path Holdings provides clinical update and 2019 business outlook
  • Dec 03, 2018: Ascentage Pharma announces oral presentation of novel, third-generation BCR-ABL inhibitor in myelogenous leukemia patients at the 60th American Society of Hematology Annual Meeting
  • Nov 21, 2018: Ascentage Pharma to present new clinical data at the ASH 2018 annual meeting
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by AbbVie Inc, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Agios Pharmaceuticals Inc, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Altor Bioscience LLC, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Arromax Pharmatech Co Ltd, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ascentage Pharma Group International, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by AstraZeneca Plc, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Atara Biotherapeutics Inc, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by AUM Biosciences Pte Ltd, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bio-Path Holdings Inc, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by BioLineRx Ltd, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Boston Biomedical Inc, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bristol-Myers Squibb Co, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Cantargia AB, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Celgene Corp, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Celularity Inc, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Daiichi Sankyo Co Ltd, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Escend Pharmaceuticals Inc, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Eureka Therapeutics Inc, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by ExCellThera Inc, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Fate Therapeutics Inc, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Fusion Pharma LLC, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Gamida Cell Ltd, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by GlaxoSmithKline Plc, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by GlycoMimetics Inc, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by GT Biopharma Inc, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Handa Pharmaceuticals LLC, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Hebei Senlang Biotechnology Inc Ltd, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by HEC Pharm Co Ltd, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Helocyte Biosciences Inc, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by HighPass Bio Inc, H2 2019
  • Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Housey Pharmaceutical Research Laboratories LLC, H2 2019

List of Figures

  • Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Top 10 Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Top 10 Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top